What is a stock summary page? Click here for an overview.
Business Description
CG Oncology Inc
NAICS : 541714
SIC : 2833
ISIN : US1569441009
Description
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1826.72 | |||||
| Equity-to-Asset | 0.97 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 75.84 | |||||
| Beneish M-Score | 35.83 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Future 3-5Y EPS without NRI Growth Rate Estimate | 47.32 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 491.83 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.98 | |||||
| 9-Day RSI | 45.67 | |||||
| 14-Day RSI | 43.77 | |||||
| 3-1 Month Momentum % | -0.9 | |||||
| 6-1 Month Momentum % | -18.1 | |||||
| 12-1 Month Momentum % | -28.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 35.32 | |||||
| Quick Ratio | 35.32 | |||||
| Cash Ratio | 34.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -20.15 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -14030.99 | |||||
| Net Margin % | -10642.4 | |||||
| FCF Margin % | -10631.73 | |||||
| ROE % | -17.82 | |||||
| ROA % | -17.27 | |||||
| ROIC % | -1583.59 | |||||
| ROC (Joel Greenblatt) % | -10851.65 | |||||
| ROCE % | -23.48 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1842.93 | |||||
| PB Ratio | 3.26 | |||||
| Price-to-Tangible-Book | 3.26 | |||||
| EV-to-EBIT | -15.49 | |||||
| EV-to-Forward-EBIT | -9.77 | |||||
| EV-to-EBITDA | -15.49 | |||||
| EV-to-Forward-EBITDA | -8.77 | |||||
| EV-to-Revenue | 2172.75 | |||||
| EV-to-Forward-Revenue | 1533.7 | |||||
| EV-to-FCF | -20.44 | |||||
| Price-to-Net-Current-Asset-Value | 3.27 | |||||
| Price-to-Net-Cash | 3.34 | |||||
| Earnings Yield (Greenblatt) % | -6.46 | |||||
| FCF Yield % | -3.68 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CGON
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CG Oncology Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.684 | ||
| EPS (TTM) ($) | -1.294 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 32.36 | ||
| 14-Day RSI | 43.77 | ||
| 14-Day ATR ($) | 1.498583 | ||
| 20-Day SMA ($) | 26.7915 | ||
| 12-1 Month Momentum % | -28.37 | ||
| 52-Week Range ($) | 23.905 - 46.99 | ||
| Shares Outstanding (Mil) | 76.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CG Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CG Oncology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
CG Oncology Inc Frequently Asked Questions
What is CG Oncology Inc(CGON)'s stock price today?
The current price of CGON is $25.95. The 52 week high of CGON is $46.99 and 52 week low is $23.91.
When is next earnings date of CG Oncology Inc(CGON)?
The next earnings date of CG Oncology Inc(CGON) is 2025-03-14 Est..
Does CG Oncology Inc(CGON) pay dividends? If so, how much?
CG Oncology Inc(CGON) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers